Ramazan Sari1, Meric A Altinoz2, Enis Ozyar3, Ayca Ersen Danyeli4, Ilhan Elmaci5,6. 1. Department of Neurosurgery, Acibadem Maslak Hospital, Istanbul, Turkey. 2. Department of Medical Biochemistry, Acibadem Mehmet Ali Aydinlar University, Istanbul, Turkey. 3. Department of Radiation Oncology, Acibadem Mehmet Ali Aydinlar University, Istanbul, Turkey. 4. Department of Pathology, Acibadem Mehmet Ali Aydinlar University, Istanbul, Turkey. 5. Department of Neurosurgery, Acibadem Maslak Hospital, Istanbul, Turkey. ilhan.elmaci@gmail.com. 6. Department of Neurosurgery, Acibadem Mehmet Ali Aydinlar University, Istanbul, Turkey. ilhan.elmaci@gmail.com.
Abstract
INTRODUCTION: Astroblastoma, MN1-altered (old name: high-grade neuroepithelial tumor/HGNET with MN1 alteration) is a recently described central nervous system tumor mostly affecting pediatric patients and profoundly young girls. Differential pathological diagnoses of these tumors include ependymoma, pleomorphic xanthoastrocytoma, embryonal tumor with multilayered rosettes, meningioma, and even glioblastoma. As the treatment approaches to these tumors differ, it is essential to increase the awareness about these tumors in the neurosurgical community. CLINICAL PRESENTATION: A 7-year-old female patient admitted with a 7-day history of headache, nausea, and vomiting. A contrasted MRI scan revealed a left parietal 4 × 4 × 5 cm mass with central necrosis and peripheral contrast enhancement. The tumor's histopathological findings were suggestive of a metastatic carcinoma with unknown primary, yet further genetic analysis revealed MN1 alteration. Peculiarly, the tumor pathomorphological features were not compatible with astroblastomas and exerted features strongly indicating a metastatic cancer; however, systemic PET and whole-body MRI failed to detect a primary malignancy. OUTCOME AND CONCLUSIONS: Eighteen months after gross-total tumor resection, an in-field and out-field multifocal recurrence developed which required a second surgery and subsequent chemo-radiotherapy. The patient is doing well for 1 year after the second treatment regimen at the time of this report. Despite the final cIMPACT6 classification in 2020 advised to define all MN1 altered brain tumors as astroblastomas, there exist prognostic differences in MN1-altered tumors with and without morphological features of astroblastoma. Rare morphological variants of MN1-altered tumors shall be recognized for their future prognostic and clinical classification. HGNET with MN1 alteration seems still be a more proper definition of such malignancies as an umbrella term.
INTRODUCTION:Astroblastoma, MN1-altered (old name: high-grade neuroepithelial tumor/HGNET with MN1 alteration) is a recently described central nervous system tumor mostly affecting pediatric patients and profoundly young girls. Differential pathological diagnoses of these tumors include ependymoma, pleomorphic xanthoastrocytoma, embryonal tumor with multilayered rosettes, meningioma, and even glioblastoma. As the treatment approaches to these tumors differ, it is essential to increase the awareness about these tumors in the neurosurgical community. CLINICAL PRESENTATION: A 7-year-old female patient admitted with a 7-day history of headache, nausea, and vomiting. A contrasted MRI scan revealed a left parietal 4 × 4 × 5 cm mass with central necrosis and peripheral contrast enhancement. The tumor's histopathological findings were suggestive of a metastatic carcinoma with unknown primary, yet further genetic analysis revealed MN1 alteration. Peculiarly, the tumor pathomorphological features were not compatible with astroblastomas and exerted features strongly indicating a metastatic cancer; however, systemic PET and whole-body MRI failed to detect a primary malignancy. OUTCOME AND CONCLUSIONS: Eighteen months after gross-total tumor resection, an in-field and out-field multifocal recurrence developed which required a second surgery and subsequent chemo-radiotherapy. The patient is doing well for 1 year after the second treatment regimen at the time of this report. Despite the final cIMPACT6 classification in 2020 advised to define all MN1 altered brain tumors as astroblastomas, there exist prognostic differences in MN1-altered tumors with and without morphological features of astroblastoma. Rare morphological variants of MN1-altered tumors shall be recognized for their future prognostic and clinical classification. HGNET with MN1 alteration seems still be a more proper definition of such malignancies as an umbrella term.
Authors: David N Louis; Pieter Wesseling; Kenneth Aldape; Daniel J Brat; David Capper; Ian A Cree; Charles Eberhart; Dominique Figarella-Branger; Maryam Fouladi; Gregory N Fuller; Caterina Giannini; Christine Haberler; Cynthia Hawkins; Takashi Komori; Johan M Kros; H K Ng; Brent A Orr; Sung-Hye Park; Werner Paulus; Arie Perry; Torsten Pietsch; Guido Reifenberger; Marc Rosenblum; Brian Rous; Felix Sahm; Chitra Sarkar; David A Solomon; Uri Tabori; Martin J van den Bent; Andreas von Deimling; Michael Weller; Valerie A White; David W Ellison Journal: Brain Pathol Date: 2020-04-19 Impact factor: 6.508
Authors: Lorena V Baroni; Carlos Rugilo; Fabiana Lubieniecki; Claudia Sampor; Candela Freytes; Liana Nobre; Jordan R Hansford; Vajiranee S Malalasekera; Michal Zapotocky; Andrew Dodgshun; Ofelia Cruz Martinez; Andres Morales La Madrid; Cinzia Lavarino; Mariona Suñol; Stefan Rutkowski; Ulrich Schuller; Eric Bouffet; Vijay Ramaswamy; Daniel Alderete Journal: Pediatr Blood Cancer Date: 2020-09-22 Impact factor: 3.167
Authors: Norman L Lehman; Aisulu Usubalieva; Tong Lin; Sariah J Allen; Quynh T Tran; Bret C Mobley; Roger E McLendon; Matthew J Schniederjan; Maria-Magdalena Georgescu; Marta Couce; Mohanpal S Dulai; Jack M Raisanen; Mousa Al Abbadi; Cheryl A Palmer; Eyas M Hattab; Brent A Orr Journal: Acta Neuropathol Commun Date: 2019-03-15 Impact factor: 7.801